Prophylaxis and therapy of gestational complications associated with endothelial dysfunction
Abstract
One of the main causes of habitual miscarriage, preeclampsia, fetal development retardation, hypertensive complications of pregnancy is a violation of microcirculation and increased intravascular coagulation. In turn, microcirculatory disorders are the result of several pathogenetic mechanisms, among which great importance is given to endothelial dysfunction. The review discusses the physiological aspects of increasing blood coagulation during pregnancy and questions of the pathogenesis of complications of gestation from the standpoint of endothelial dysfunction and increased coagulability of the blood. Illuminates diseases and conditions, the risk of which is associated with endothelial dysfunction. Methods of pharmacotherapy aimed at the prevention and treatment of gestational complications are considered. Particular attention is paid to the drug sulodexide - anticoagulant, a representative of the glycosaminoglycan family, which has a unique profile of a predominantly positive effect on endothelial function.
About the Author
I. V. Kuznetsova
First Moscow State Medical University n.a. I.M. Sechenov
Russian Federation
Russian Federation
References
1. Макацария А.Д., Бреннер Б., Бицадзе В.О., Акиньшина С.В. Системный венозный и артериальный тромбоэмболизм в акушерско-гинекологической практике. М.: МИА, 2016: 1008 с.
2. Struble E., Harrouk W., DeFelice A., Tesfamariam B. Nonclinical Aspects of Venous Thrombosis in Pregnancy. Birth Defects Res C Embryo Today 2015; 105 (3): 190-200.
3. Han L., Liu X., Li H., et al. Blood Coagulation Parameters and Platelet Indices: Changes in Normal and Preeclamptic Pregnancies and Predictive Values for Preeclampsia. PLoS ONE. 2014; 9 (12): e114488.
4. Virkus R.A., Lokkegaard E.C., Bergholt T., Mogensen U., Langhoff-Roos J., Lidegaard Ш. Venous thromboembolism in pregnant and puerperal women in Denmark 19952005. A national cohort study. Thromb Haemost 2011; 106 (2): 304-309.
5. Possomato-Vieira J.S., Khalil R.A. Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol 2016; 77: 361-431.
6. Daiber A., Steven S., Weber A., et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol 2017; 174 (12): 1591-1619.
7. Gandley R.E., Althouse A., Jeyabalan A., et al. Low Soluble Syndecan-1 Precedes Preeclampsia PLoS One. 2016; 11 (6): e0157608.
8. Garrido-Gomez T., Ona K., Kapidzic M., et al. Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. Development 2017; 144 (5): 767-777.
9. Myatt L, Muralimanoharan S., Maloyan A. Effect of preeclampsia on placental function: influence of sexual dimorphism, microRNA’s and mitochondria. Adv Exp Med Biol 2014; 814: 133-146.
10. Shi Z., Long W., Zhao C., et al. Comparative pro-teomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia PLoS One 2013; 8 (5): e64351.
11. Макаров О.В., Волкова Е.В., Винокурова И.Н., Джохадзе Л.С. Лечение артериальной гипертензии у беременных. Проблемы репродукции. 2011; 6: 87-92.
12. Heimrath J., Paprocka M., Czekanski A., et al. Pregnancy-induced hypertension is accompanied by decreased number of circulating endothelial cells and circulating endothelial progenitor cells. Arch Immunol Ther Exp (Warsz). 2014; 62 (4): 353-356.
13. Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.-M., Vandvik P.O. VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2 Suppl): e691S-e736S.
14. Haram K., Mortensen J.H., Nagy B. Genetic Aspects of Preeclampsia and the HELLP Syndrome. J Preg 2014; 2014: 910751.
15. Ormesher L., Simcox L.E., Tower C., Greer I.A. “To test or not to test”, the arguments for and against thrombophilia testing in obstetrics. Obstet Med 2017; 10 (2): 61-66.
16. Chaturvedi S., McCrae K.R. The antiphospholipid syndrome: still an enigma. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2015; 2015: 53-60.
17. Di Prima F.A.F., Valenti O., Hyseni E., et al. Antiphospholipid Syndrome during pregnancy: the state of the art. J PrenatMed. 2011; 5 (2): 41-53.
18. Emmi G., Silvestri E., Squatrito D., et al. An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions. Sci World J 2014; 2014: 341342.
19. Willis R., Pierangeli S.S. Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights. 2011; 2 (2): 35-52.
20. Mulla M.J., Brosens J.J., Chamley L.W., et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR 4/MyD 88 pathway. Am J Reprod Immunol 2009; 62 (2): 96-111.
21. Chighizola C.B., Ubiali T., Meroni P.L. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management - An Insight into Future Approaches. J Immunol Res 2015; 2015: 951424.
22. Adage T., Piccinini A.-M., Falsone A., et al. Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br J Pharmacol 2012; 167 (6): 1195-1205.
23. Smythe M.A., Priziola J., Dobesh P.P., Wirth D., Cuker A., Wittkowsky A.K. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016; 41: 165-186.
24. Arepally G.M. Heparin-induced thrombocytopenia. Blood. 2017; 129 (21): 2864-2872.
25. Garcia D.A., Baglin T.P., Weitz J.I., Samama M.M. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2 Suppl): e24S-e43S.
26. Морозов К.М., Колбин А.С., Галанкин Т.Л. Сетевой мета-анализ эффективности применения парнапарина для профилактики венозных тромбоэмболических осложнений при хирургических вмешательствах. Тромбоз, гемостаз и реология. 2018; 1: 31-39
27. Hoppensteadt D.A., Fareed J. Pharmacological profile of sulodexide. Int Angiol 2014; 33 (3): 229-235.
28. Coccheri S., Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013; 8: 49-65.
29. Masola V., Zaza G., Onisto M., et al. Glycosaminoglycans, proteoglycans and sulodex-ide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33 (3): 243-254.
30. Karthikeyan V.J., Lip G.Y. Endothelial damage / dysfunction and hypertension in pregnancy. Front Biosci. (Elite Ed). 2011; 1 (3): 1100-1108.
31. LaMarca B. Endothelial dysfunction; an important mediator in the Pathophysiology of Hypertension during Preeclampsia. Minerva Ginecol2012; 64 (4): 309-320.
32. Li T., Liu X., Zhao Z., et al. Sulodexide recovers endothelial function through reconstructing glycocalyx in the balloon-injury rat carotid artery model. Oncotarget 2017; 8(53): 91350-91361.
33. Eskens B.J.M., Vink H., VanTeeffelen. Improvement of Insulin Reistance in Diet-Induced Obese Mice by Sulodexide, an Endothelial Glycocalyx Mimetic. J Endocrinol Diabetes Obes 2014; 2 (2): 1027.
34. Broekhuizen L.N., Lemkes B.A., Mooij H.L., et al. Effect of sulodexide on endothelial glyco-calyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53 (12): 2646-2655.
35. Gabryel B., Jarzabek K., Machnik G., et al. Superoxide dismutase 1 and glutathione peroxidase 1 are involved in the protective effect of sulodexide on vascular endothelial cells exposed to oxygen-glucose deprivation. Microvasc. Res 2015; 103: 26-35.
36. Попова Т.А., Перфилова В.Н., Жакупова Г.А. и соавт. Влияние сулодексида на функциональное состояние митохондрий плаценты самок крыс с экспериментальной преэклампсией. Биомедицинская химия 2016; 62 (5): 572-576.
37. Мондоева С.С., Суханова Г.А., Подзолкова Н.М. Применение сулодексида в акушерской практике: обзор литературы. Проблемы репродукции 2008; 2: 73-76.
38. Федоренко А.В., Дикке Г.Б. Плацентарная недостаточность у беременных с гестационной артериальной гипертензией и патогенетический подход к ее профилактике. Фарматека 2015; 3.
39. Olde Engberink RH, Rorije NM, Lambers Heerspink HJ, et al. The blood pressure lowering potential of sulodexide - a systematic review and meta-analysis. Br J Clin Pharmacol. 2015; 80 (6): 1245-1253.
40. Мозговая Е.В., Аржанова О.Н. Медикаментозная терапия и профилактика гестоза. Методические рекомендации. СПб: Издательство Н-Л, 2008; 43с.
41. Щербаков А.Ю., Меликова Т.А. Мониторинг эффективности применения натурального антикоагулянта сулодексид у беременных с аутоиммунным гипертиреозом на фоне гипергомоцистеинемии. Патология. 2017; 14 (39): 57-56.
42. Gerotziafas G.T., Van Dreden P., Mathieu d’Argent E., et al. Impact of blood hypercoagulability on in vitro fertilization outcomes: a prospective longitudinal observational study. Thromb J 2017; 15: 9.
43. Andreozzi G.M., Bignamini A.A., Davi G., et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015; 132 (20): 1891-1897.
44. Mosca L., Benjamin E.J., Berra K., et al. Effectiveness-based guidelines for the prevention of CVD in women - 2011 update. A guideline from the American Heart Association. Circulation 2011; 123 (11): 1243-1262.
Review
For citations:
Kuznetsova I.V. Prophylaxis and therapy of gestational complications associated with endothelial dysfunction. Medical alphabet. 2018;3(22):23. (In Russ.)
Views:
424
Email this article 